Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.446
Sell
RSI(14)
23.855
Sell
STOCH(KDJ)(9,3,3)
22.349
Sell
ATR(14)
0.373
High Vlolatility
CCI(14)
-165.564
Sell
Williams %R
81.028
Oversold
TRIX(12,20)
-0.490
Sell
StochRSI(14)
12.469
Oversold
Search
TriSalus Life Sciences Inc
TLSIAdd to Watchlist
2.680USD
+0.160+6.35%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
164.60MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of TriSalus Life Sciences Inc
Currency: USD Updated: 2026-05-15Key Insights
TriSalus Life Sciences Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 106 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 9.20.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
TriSalus Life Sciences Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
TriSalus Life Sciences Inc Highlights
StrengthsRisks
TriSalus Life Sciences, Inc. is an oncology-focused medical technology company. The Company is seeking to transform outcomes for patients with solid tumors by integrating its delivery technology with standard-of-care therapies, and with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and technology applications. The Company’s platform includes devices that utilize a proprietary drug delivery technology and a clinical-stage investigational immunotherapy. The Company’s two Food and Drug Administration (FDA)-cleared devices use its proprietary Pressure-Enabled Drug Delivery (PEDD) approach to deliver a range of therapeutics: the TriNav Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. PEDD technology is a novel delivery approach designed to address the anatomic limitations of arterial infusion for the pancreas.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 143.91% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 45.15M.
Fairly Valued
The company’s latest PE is -1.89, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 14.73M shares, increasing 17.64% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 3.46K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 3.19.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
9.200
Target Price
+265.08%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-15The current financial score of TriSalus Life Sciences Inc is 7.68, ranking 67 out of 382 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 8.90M, representing a year-over-year decrease of 2.92%, while its net profit experienced a year-over-year decrease of 113.88%.
Score
Financials
6.25
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.08
Operational Efficiency
9.38
Growth Potential
8.31
Shareholder Returns
7.36
TriSalus Life Sciences Inc's Company Valuation
Currency: USD Updated: 2026-05-15The current valuation score of TriSalus Life Sciences Inc is 6.25, ranking 294 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.89, which is -100.00% below the recent high of 0.00 and -188.32% above the recent low of -5.44.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 106/382
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-15The current earnings forecast score of TriSalus Life Sciences Inc is 8.00, ranking 161 out of 382 in the Biotechnology & Medical Research industry. The average price target is 11.00, with a high of 16.00 and a low of 9.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
9.200
Target Price
+265.08%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
554
Total
5
Median
6
Average
Company name
Ratings
Analysts
TriSalus Life Sciences Inc
TLSI
5
CRISPR Therapeutics AG
CRSP
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Beigene Ltd
ONC
26
Ionis Pharmaceuticals Inc
IONS
25
1
2
3
...
111
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-15The current price momentum score of TriSalus Life Sciences Inc is 6.80, ranking 149 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 4.29 and the support level at 1.64, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
3.394
Sell
MA10
3.947
Sell
MA20
4.221
Sell
MA50
4.172
Sell
MA100
4.834
Sell
MA200
4.962
Sell
Institutional Confidence
Currency: USD Updated: 2026-05-15Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-15The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of TriSalus Life Sciences Inc is 2.71, ranking 199 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 0.49. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
0.47
VaR
+5.38%
240-Day Maximum Drawdown
+66.40%
240-Day Volatility
+88.47%
Return
Best Daily Return
60 days
+18.22%
120 days
+18.22%
5 years
+33.61%
Worst Daily Return
60 days
-41.45%
120 days
-41.45%
5 years
-41.45%
Sharpe Ratio
60 days
-1.48
120 days
-0.70
5 years
-0.15
Risk Assessment
Maximum Drawdown
240 days
+66.40%
3 years
+100.00%
5 years
+100.00%
Return-to-Drawdown Ratio
240 days
-0.73
3 years
-0.25
5 years
-0.14
Skewness
240 days
-2.03
3 years
-0.07
5 years
-0.11
Volatility
Realised Volatility
240 days
+88.47%
5 years
--
Standardised True Range
240 days
+12.91%
5 years
+37.56%
Downside Risk-Adjusted Return
120 days
-72.04%
240 days
-72.04%
Maximum Daily Upside Volatility
60 days
+70.08%
Maximum Daily Downside Volatility
60 days
+113.45%
Liquidity
Average Turnover Rate
60 days
+0.90%
120 days
+0.67%
5 years
--
Turnover Deviation
20 days
+380.59%
60 days
+186.56%
120 days
+112.77%
Peer Comparison
Biotechnology & Medical Research
TriSalus Life Sciences Inc
TLSI
6.39 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.48 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Exelixis Inc
EXEL
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
